ePrints

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Lookup NU author(s): Professor David Jones

Downloads

• Accepted version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Publication metadata

Author(s): Jones DEJ, Boudes P, Swain M, Bowlus C, Galambos M, Bacon B, Doerffel Y, Gitlin N, Gordon S, Odin J, Sheridan D, Wörns M-A, Clark V, Corless L, Hartmann H, Jonas ME, Kremer A, Mells G, Buggisch P, Freilich B, Levy C, Vierling J, Bernstein D, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman M, Smith J, Choi Y-J, Steinberg A, Varga M, Chera H, Martin R, McWherter C, Hirschfield G

Publication type: Article

Publication status: Published

Journal: Lancet Gastroenterology and Hepatology

Year: 2017

Volume: 2

Issue: 10

Pages: 716-726

Print publication date: 01/10/2017

Online publication date: 14/08/2017

Acceptance date: 12/07/2017

Date deposited: 07/09/2017

ISSN (print): 2468-1253

ISSN (electronic): 2468-1156

Publisher: Elsevier

URL: https://doi.org/10.1016/S2468-1253(17)30246-7

DOI: 10.1016/S2468-1253(17)30246-7

Altmetrics

Share